
Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
Astronauts welcome arrival of new crewmates | On the International Space Station this week Nov. 24-28, 2025
Meet the Stars of the Feline World: Well known Pet Feline Varieties
Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
Tech giants accused of not complying with Australian social media ban
Find the Keys to Fruitful Venture The board: Conveying Results on Time
A Manual for the Right SUV for Seniors
All that You Really want to Be familiar with Dental Inserts Facilities
The World's Dazzling Regular Miracles













